Author:
Pi Chao,Li Lanmei,Fu Shaozhi,Yang Hongru,Huang Shaoqiu,Zou Yonggen,Zhao Ling,Wei Yumeng
Funder
Youth Science and technology innovation research team
Basic research fund of the science and technology department of Sichuan province of China
the Joint Fund of Luzhou City and Southwest Medical University
Science and Technology Fund of Luzhou science and technology and Human Resources Bureau
Science and Technology Innovation Team from Jiucheng Science and Technology Talent Cultivation Plan in Luzhou City
Publisher
Springer Science and Business Media LLC
Subject
Organic Chemistry,Clinical Biochemistry,Biochemistry,Analytical Chemistry
Reference34 articles.
1. Yasuo W, Masahiro O, Akira J, Hidefumi N, Sachiko T, Mitsuhiko T, Shiro I (2007) A phase II study of weekly paclitaxel for advanced or recurrent breast cancer. Gan To Kagaku Ryoho 34:1041–1045
2. Xu FF, Wang FL, Yang T, Sheng Y, Zhong T, Chen Y (2014) Differential drug resistance acquisition to doxorubicin and paclitaxel in breast cancer cells. Cancer Cell Int 14:1–13
3. Mo Q, Zhang Y, Jin X, Gao Y, Wu Y, Hao X, Gao Q, Chen P (2016) Geldanamycin, an inhibitor of Hsp90, increases paclitaxel-mediated toxicity in ovarian cancer cells through sustained activation of the p38/H2AX axis. Tumor Biol 37:1–11
4. Wei YM, Pu XL, Zhao L (2017) Preclinical studies for the combination of paclitaxel and curcumin in cancer therapy (review). Oncol Rep 37:3159–3166
5. Yang D, Ding DL, Jiang HY, Shi JR, Salvi R, Roth JA (2014) Ototoxicity of paclitaxel in rat cochlear organotypic cultures. Toxico Appl Pharm 280:526–533
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献